| [1] |
United Nations, Department of Economic and Social Affairs. Population division contraceptive use by method 2019 (data booklet)[M]. New York: United Nations, 2019. DOI: 10.18356/1bd58a10-en. |
| [2] |
国务院第七次全国人口普查领导小组办公室. 中国人口普查年鉴：2020[M]. 北京：中国统计出版社，2022.
|
| [3] |
Sands MI. Oral contraceptives and cardiovascular risk[J]. Drug Therap Bullet, 2000, 38(1): 1-5. DOI: 10.1136/dtb.2000.3811-a.
|
| [4] |
Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study[J]. Int J Cancer, 2003, 105(6): 844-850. DOI: 10.1002/ijc.11167.
|
| [5] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [6] |
|
| [7] |
Arshadi M, Hesari E, Ahmadinezhad M, et al. The association between oral contraceptive pills and ovarian cancer risk: a systematic review and Meta-analysis[J]. Bull Cancer, 2024, 111(10): 918-929. DOI: 10.1016/j.bulcan.2024.05.010.
|
| [8] |
Karlsson T, Johansson T, Höglund J, et al. Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers[J]. Cancer Res, 2021, 81(4): 1153-1162. DOI: 10.1158/0008-5472.CAN-20-2476.
|
| [9] |
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87，303 controls[J]. Lancet, 2008, 371(9609): 303-314. DOI: 10.1016/S0140-6736(08)60167-1. |
| [10] |
Chen S, Li L, Wang H, et al. Oral contraceptives use and ovarian cancer risk in Chinese BRCA mutation carriers: a case-control study[J]. Gynecol Oncol, 2025, 157(2): 389-395. DOI: 10.1016/j.ygyno.2025.02.015.
|
| [11] |
Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and Meta-analysis[J]. J Clin Oncol, 2013, 31(33): 4188-4198. DOI: 10.1200/JCO.2013.48.9021.
|
| [12] |
Schrijver LH, Antoniou AC, Olsson H, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study[J]. Am J Obstet Gynecol, 2021, 225(1): 51.e1-51.e17. DOI: 10.1016/j.ajog.2021.01.014.
|
| [13] |
Beral V, Million Women Study Collaborators, Bull D, et al. Ovarian cancer and hormone replacement therapy in the million women study[J]. Lancet, 2007, 369(9574): 1703-1710. DOI: 10.1016/S0140-6736(07)60534-0.
|
| [14] |
Gaitskell K, Green J, Pirie K, et al. Tubal ligation and ovarian cancer risk in a large cohort: substantial variation by histological type[J]. Int J Cancer, 2016, 138(5): 1076-1084. DOI: 10.1002/ijc.29856.
|
| [15] |
Fernandes I, Coelho R, Figueiredo-Dias M, et al. The role of progesterone in ovarian cancer: from tumour suppression to therapeutic target：an updated mini-review[J]. Eur J Gynaecol Oncol, 2025, 46(10): 5-13. DOI: 10.22514/ejgo.2025.126.
|
| [16] |
Avramenko AS, Flanagan JM. An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use[J]. Clin Epigenetics, 2023, 15(1): 165. DOI: 10.1186/s13148-023-01584-9.
|
| [17] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708.
|
| [18] |
|
| [19] |
|
| [20] |
Iversen L, Fielding S, Lidegaard Ø，et al. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women[J]. Contraception, 2020, 102(3): 152-158. DOI: 10.1016/j.contraception.2020.06.008.
|
| [21] |
World Health Organization. Cervical cancer[R/OL]. (2025-12-02) [2026-04-07].
URL
|
| [22] |
|
| [23] |
Moodley M, Moodley J, Chetty R, et al. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review[J]. Int J Gynecol Cancer, 2003, 13(2): 103-110. DOI: 10.1046/j.1525-1438.2003.13030.x.
|
| [24] |
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16，573 women with cervical cancer and 35，509 women without cervical cancer from 24 epidemiological studies[J]. Lancet, 2007: 370(9599): 1609-1621. DOI: 10.1016/S0140-6736(07)61684-5. |
| [25] |
International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16, 563 women with cervical carcinoma and 33，542 women without cervical carcinoma from 25 epidemiological studies[J]. Int J Cancer, 2006, 119(5): 1108-1124. DOI: 10.1002/ijc.21953. |
| [26] |
Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention[J]. J Natl Cancer Inst, 2006, 98(5): 303-315. DOI: 10.1093/jnci/djj067.
|
| [27] |
Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer: a systematic review & Meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2020, 247: 163-175. DOI: 10.1016/j.ejogrb.2020.02.014.
|
| [28] |
Marks M, Gravitt PE, Gupta SB, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand[J]. J Infect Dis, 2011, 204(10)：1505-1513. DOI: 10.1093/infdis/jir560.
|
| [29] |
Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review[J]. Cancer Epidemiol Biomarkers Prev, 2013, 22(11): 1931-1943. DOI: 10.1158/1055-9965.EPI-13-0298.
|
| [30] |
Moodley M, Sewart S, Herrington CS, et al. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer[J]. Int J Gynecol Cancer, 2003, 13(6): 834-842. DOI: 10.1111/j.1525-1438.2003.13380.x.
|
| [31] |
Ramachandran B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis[J]. Endocr Relat Cancer, 2017, 24(4): R99-R108. DOI： 10.1530/ERC-16-0571.
|
| [32] |
Shew ML, McGlennen R, Zaidi N, et al. Oestrogen receptor transcripts associated with cervical human papillomavirus infection[J]. Sex Transm Infect, 2002, 78(3): 210-214. DOI: 10.1136/sti.78.3.210.
|
| [33] |
Hellberg D. Sex steroids and cervical cancer[J]. Anticancer Res, 2012, 32(8): 3045-3054.
|
| [34] |
Torres-de la Roche LA, Acevedo-Mesa A, Lizarazo IL, et al. Hormonal contraception and the risk of breast cancer in women of reproductive age: a Meta-analysis[J]. Cancers (Basel), 2023, 15(23): 5624. DOI: 10.3390/cancers15235624.
|
| [35] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006.
|
| [36] |
Burchardt NA, Eliassen AH, Shafrir AL, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses′ Health Study Ⅱ：a prospective cohort study[J]. Am J Obstet Gynecol, 2022, 226(6): 821.e1-821.e26. DOI: 10.1016/j.ajog.2021.12.022.
|
| [37] |
Fitzpatrick D, Pirie K, Reeves G, et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and Meta-analysis[J]. PLoS Med, 2023, 20(3): e1004188. DOI: 10.1371/journal.pmed.1004188.
|
| [38] |
|
| [39] |
Ozmen V, Ozcinar B, Karanlik H, et al. Breast cancer risk factors in Turkish women: a university hospital based nested case control study[J]. World J Surg Oncol, 2009, 7: 37. DOI: 10.1186/1477-7819-7-37.
|
| [40] |
Schrijver LH, Olsson H, Phillips KA, et al. Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study[J]. JNCI Cancer Spectr, 2018, 2(2): pky023. DOI: 10.1093/jncics/pky023.
|
| [41] |
Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers [J]. Breast Cancer Res Treat, 2014, 143(3): 579-586. DOI: 10.1007/s10549-013-2823-4.
|